Ribo Life Science Marks New Era by Listing on Hong Kong Stock Exchange

Ribo Life Science Makes Its Debut on the Hong Kong Stock Exchange

An Overview of the Exciting IPO

On January 9, 2026, Ribo Life Science Co., Ltd. (stock code: 06938.HK), a front-runner in small interfering RNA (siRNA) therapeutics, achieved an important milestone by listing on the Main Board of the Hong Kong Stock Exchange. This event signifies not just a personal victory for Ribo but also a step forward for the entire Chinese biopharmaceutical sector, particularly in the field of siRNA technology.

Ribo's successful IPO is a testament to the growing importance and demand for innovative therapies that target critical diseases through advanced technologies. Its shares were offered at HKD 57.97, resulting in a substantial gross raise exceeding 1.8 billion Hong Kong dollars. The offering saw a staggering oversubscription, with figures over 100 times for Hong Kong public offering and 16.7 times for the international placement. This interest underscores the global confidence investors have in the siRNA landscape and Ribo's potential.

Institutional Confidence in Ribo

The initial public offering attracted a number of cornerstone investors, including prominent names such as Arc Avenue, Ivy Rock, Springs Capital, among others. This blend of institutional support further cements the strong belief in Ribo's growth strategy and long-term objectives. Dr. Zicai Liang, Ribo's Founder, Chairman, and CEO, remarked on the significance of this milestone, thanking the investors for their trust. He emphasized that this listing positions the company to leverage international capital markets, accelerating clinical developments and the commercialization of their siRNA innovations.

Strategic Utilization of IPO Proceeds

The substantial capital raised will primarily be allocated to four key areas:
1. Advancing Clinical Trials: Support for global multicenter clinical trials focused on core products.
2. Research and Development: Funding for preclinical and clinical developments across their extensive pipeline.
3. Technology Enhancement: Continuous upgrading of siRNA delivery technologies and platforms.
4. Operational Expenses: Replenishing working capital alongside routine operational necessities.

Ribo boasts a comprehensive R&D platform founded on robust intellectual property rights. Their innovative liver-targeting RiboGalSTARTM delivery technology, crafted with precision, has ushered several products into Phase II clinical trials. Ribo operates research centers in strategic locations including Suzhou, Beijing, and Gothenburg, ensuring a global network that supports drug development from initial discovery through to clinical trials.

Conclusion: A Bright Future Ahead

The listing is jointly facilitated by China International Capital Corporation and Citigroup, both of which provided invaluable expertise to navigate the capital markets. As Ribo Life Science continues on its promising journey, it remains committed to delivering transformative therapies that address major health challenges. With this successful IPO, Ribo is well-positioned to enhance its impact in the biopharmaceutical world and ultimately improve therapeutic options for patients worldwide.

For more information, visit Ribo Life Science.